Safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients
Authors:
Samuel J van Bohemen,
Jeffrey M Rogers,
Aleksandra Alavanja,
Andrew Evans,
Noel Young,
Philip C Boughton,
Joaquin Valderrama,
Andre Z Kyme
Abstract:
This study assessed the safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients. The device captured electroencephalography (EEG) and electrocardiography (ECG) data to compute an ECG-based metric termed the Electrocardiography Brain Perfusion index (EBPi), which may function as a proxy for cerebral blood flow (CBF). Seventeen ischaemic stroke patients wore the…
▽ More
This study assessed the safety, feasibility, and acceptability of a novel device to monitor ischaemic stroke patients. The device captured electroencephalography (EEG) and electrocardiography (ECG) data to compute an ECG-based metric termed the Electrocardiography Brain Perfusion index (EBPi), which may function as a proxy for cerebral blood flow (CBF). Seventeen ischaemic stroke patients wore the device for nine hours and reported feedback at 1, 3, 6 and 9 hours regarding user experience, comfort, and satisfaction (acceptability). Safety was assessed as the number of adverse events reported. Feasibility was assessed as the percentage of uninterrupted EEG/ECG data recorded (data capture efficiency). No adverse events were reported, only minor incidences of discomfort. Overall device comfort (92.5% +/- 10.3%) and data capture efficiency (95.8% +/- 6.8%) were very high with relatively low variance. The device did not restrict participants from receiving clinical care and rarely (n=6) restricted participants from undertaking routine tasks. This study provides a promising evidence base for the deployment of the device in a clinical setting. If clinically validated, EBPi may be able to detect CBF changes to monitor early neurological deterioration and treatment outcomes, thus filling an important gap in current monitoring options.
△ Less
Submitted 25 March, 2024;
originally announced March 2024.
